Xilio Therapeutics (XLO) Competitors $0.68 -0.01 (-0.93%) As of 06/12/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock XLO vs. EPRX, LRMR, FTLF, ALEC, HURA, BDTX, ENTA, CGEN, GLSI, and TARAShould you be buying Xilio Therapeutics stock or one of its competitors? The main competitors of Xilio Therapeutics include Eupraxia Pharmaceuticals (EPRX), Larimar Therapeutics (LRMR), FitLife Brands (FTLF), Alector (ALEC), TuHURA Biosciences (HURA), Black Diamond Therapeutics (BDTX), Enanta Pharmaceuticals (ENTA), Compugen (CGEN), Greenwich LifeSciences (GLSI), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Xilio Therapeutics vs. Its Competitors Eupraxia Pharmaceuticals Larimar Therapeutics FitLife Brands Alector TuHURA Biosciences Black Diamond Therapeutics Enanta Pharmaceuticals Compugen Greenwich LifeSciences Protara Therapeutics Eupraxia Pharmaceuticals (NASDAQ:EPRX) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, earnings, risk, profitability, analyst recommendations, institutional ownership, community ranking, media sentiment and dividends. Does the MarketBeat Community prefer EPRX or XLO? Xilio Therapeutics received 9 more outperform votes than Eupraxia Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave Eupraxia Pharmaceuticals an outperform vote while only 76.47% of users gave Xilio Therapeutics an outperform vote. CompanyUnderperformOutperformEupraxia PharmaceuticalsOutperform Votes4100.00% Underperform VotesNo VotesXilio TherapeuticsOutperform Votes1376.47% Underperform Votes423.53% Do analysts recommend EPRX or XLO? Eupraxia Pharmaceuticals presently has a consensus target price of $10.50, indicating a potential upside of 170.62%. Xilio Therapeutics has a consensus target price of $4.00, indicating a potential upside of 485.14%. Given Xilio Therapeutics' higher possible upside, analysts plainly believe Xilio Therapeutics is more favorable than Eupraxia Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eupraxia Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33Xilio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings & valuation, EPRX or XLO? Eupraxia Pharmaceuticals has higher earnings, but lower revenue than Xilio Therapeutics. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Xilio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEupraxia PharmaceuticalsN/AN/A-$28.22M-$0.76-5.11Xilio Therapeutics$9.27M3.82-$76.40M-$0.84-0.81 Does the media refer more to EPRX or XLO? In the previous week, Xilio Therapeutics had 3 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 4 mentions for Xilio Therapeutics and 1 mentions for Eupraxia Pharmaceuticals. Xilio Therapeutics' average media sentiment score of 1.02 beat Eupraxia Pharmaceuticals' score of 0.93 indicating that Xilio Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Eupraxia Pharmaceuticals Positive Xilio Therapeutics Positive Which has more volatility and risk, EPRX or XLO? Eupraxia Pharmaceuticals has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500. Comparatively, Xilio Therapeutics has a beta of -0.01, suggesting that its stock price is 101% less volatile than the S&P 500. Do insiders and institutionals hold more shares of EPRX or XLO? 54.3% of Xilio Therapeutics shares are held by institutional investors. 5.2% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is EPRX or XLO more profitable? Xilio Therapeutics' return on equity of -211.50% beat Eupraxia Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Eupraxia PharmaceuticalsN/A -219.64% -96.00% Xilio Therapeutics N/A -211.50%-80.31% SummaryXilio Therapeutics beats Eupraxia Pharmaceuticals on 10 of the 17 factors compared between the two stocks. Get Xilio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for XLO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XLO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XLO vs. The Competition Export to ExcelMetricXilio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$35.40M$6.92B$5.61B$8.62BDividend YieldN/A2.55%5.28%4.17%P/E Ratio-0.408.6727.2119.96Price / Sales3.82262.53408.49157.63Price / CashN/A65.8538.2534.64Price / Book0.516.597.074.69Net Income-$76.40M$143.75M$3.23B$248.14M7 Day Performance-2.34%0.68%0.68%0.91%1 Month Performance-40.56%11.93%9.59%5.71%1 Year Performance-34.90%4.33%32.02%14.71% Xilio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XLOXilio Therapeutics3.5736 of 5 stars$0.68-0.9%$4.00+485.1%-35.5%$35.40M$9.27M-0.4070Positive NewsShort Interest ↓Gap DownEPRXEupraxia Pharmaceuticals2.3124 of 5 stars$3.94+1.5%$10.50+166.5%+43.2%$141.25MN/A-5.4729LRMRLarimar Therapeutics2.7689 of 5 stars$2.20-2.2%$19.67+793.9%-69.8%$140.86MN/A-1.9130Short Interest ↓FTLFFitLife Brands4.2013 of 5 stars$14.81+1.2%$20.50+38.4%-6.1%$139.08M$63.86M17.5320Short Interest ↑ALECAlector3.3815 of 5 stars$1.38+3.8%$4.00+189.9%-65.5%$137.99M$88.34M-0.81270Short Interest ↑Analyst RevisionHURATuHURA BiosciencesN/A$3.12+2.0%$12.67+306.0%N/A$136.28MN/A0.00N/ABDTXBlack Diamond Therapeutics3.4851 of 5 stars$2.37+7.7%$14.60+516.0%-61.1%$134.77M$70M-1.7890Positive NewsENTAEnanta Pharmaceuticals3.8906 of 5 stars$6.29+6.1%$17.25+174.2%-44.3%$134.46M$64.46M-1.27160CGENCompugen2.3861 of 5 stars$1.50+2.0%$4.00+166.7%-18.6%$133.86M$27.59M75.0070Positive NewsGap DownGLSIGreenwich LifeSciences2.2913 of 5 stars$9.64-2.1%$39.00+304.6%-33.8%$128.87MN/A-12.053Positive NewsTARAProtara Therapeutics2.5004 of 5 stars$3.30+8.6%$20.50+521.2%+23.0%$127.32MN/A-1.1730Positive NewsAnalyst RevisionGap Up Related Companies and Tools Related Companies EPRX Competitors LRMR Competitors FTLF Competitors ALEC Competitors HURA Competitors BDTX Competitors ENTA Competitors CGEN Competitors GLSI Competitors TARA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XLO) was last updated on 6/13/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xilio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xilio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XLO Stock Free XLO Stock Alerts